186 related articles for article (PubMed ID: 34347045)
1. Organs-on-chip models for cardiovascular drug development.
Zimmermann WH
Cardiovasc Res; 2021 Nov; 117(12):e164-e165. PubMed ID: 34347045
[No Abstract] [Full Text] [Related]
2. The application of phenotypic high-throughput screening techniques to cardiovascular research.
Etzion Y; Muslin AJ
Trends Cardiovasc Med; 2009 Aug; 19(6):207-12. PubMed ID: 20211437
[TBL] [Abstract][Full Text] [Related]
3. The Future of Cardiovascular Therapeutics.
MacRae CA; Roden DM; Loscalzo J
Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
[No Abstract] [Full Text] [Related]
4. Biomimetic microsystems for cardiovascular studies.
Inbody SC; Sinquefield BE; Lewis JP; Horton RE
Am J Physiol Cell Physiol; 2021 May; 320(5):C850-C872. PubMed ID: 33760660
[TBL] [Abstract][Full Text] [Related]
5. Leptin and the cardiovascular system - a target for therapeutic interventions.
Beltowski J
Curr Pharm Des; 2014; 20(4):601-2. PubMed ID: 23688018
[No Abstract] [Full Text] [Related]
6. Therapeutic potential of neuregulin-1 in cardiovascular disease.
Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
[TBL] [Abstract][Full Text] [Related]
7. Role of nitroxyl (HNO) in cardiovascular system: From biochemistry to pharmacology.
Sun HJ; Wu ZY; Cao L; Zhu MY; Nie XW; Huang DJ; Sun MT; Bian JS
Pharmacol Res; 2020 Sep; 159():104961. PubMed ID: 32474086
[TBL] [Abstract][Full Text] [Related]
8. Novel Beneficial Cardiovascular Effects of Natural Activators of Autophagy.
Frati G; Vecchione C; Sciarretta S
Circ Res; 2018 Sep; 123(8):947-949. PubMed ID: 30355035
[No Abstract] [Full Text] [Related]
9. Effects of geranylgeranylacetone upon cardiovascular diseases.
Zeng S; Wang H; Chen Z; Cao Q; Hu L; Wu Y
Cardiovasc Ther; 2018 Aug; 36(4):e12331. PubMed ID: 29656548
[TBL] [Abstract][Full Text] [Related]
10. Relaxin' the Heart: A Novel Therapeutic Modality.
Raleigh JM; Toldo S; Das A; Abbate A; Salloum FN
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):353-62. PubMed ID: 26589290
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen Sulfide Switch Phenomenon Regulating Autophagy in Cardiovascular Diseases.
Luo W; Gui DD; Yan BJ; Ren Z; Peng LJ; Wei DH; Liu LS; Zhang DW; Jiang ZS
Cardiovasc Drugs Ther; 2020 Feb; 34(1):113-121. PubMed ID: 32090295
[TBL] [Abstract][Full Text] [Related]
12. cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype.
Dang TA; Schunkert H; Kessler T
J Cardiovasc Pharmacol; 2020 Jun; 75(6):516-525. PubMed ID: 32487847
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential.
Monteiro-Pinto C; Adão R; Leite-Moreira AF; Brás-Silva C
Cardiovasc Drugs Ther; 2019 Oct; 33(5):599-613. PubMed ID: 31512017
[TBL] [Abstract][Full Text] [Related]
14. Colchicine for the treatment of cardiovascular diseases: old drug, new targets.
Andreis A; Imazio M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2021 Jan; 22(1):1-8. PubMed ID: 32858634
[TBL] [Abstract][Full Text] [Related]
15. Effects of imperatorin in the cardiovascular system and cancer.
Nasser MI; Zhu S; Hu H; Huang H; Guo M; Zhu P
Biomed Pharmacother; 2019 Dec; 120():109401. PubMed ID: 31622950
[TBL] [Abstract][Full Text] [Related]
16. Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease.
Lizotte-Waniewski M; Brew K; Hennekens CH
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):368-71. PubMed ID: 26703451
[TBL] [Abstract][Full Text] [Related]
17. Kidney-on-a-chip: untapped opportunities.
Ashammakhi N; Wesseling-Perry K; Hasan A; Elkhammas E; Zhang YS
Kidney Int; 2018 Dec; 94(6):1073-1086. PubMed ID: 30366681
[TBL] [Abstract][Full Text] [Related]
18. P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease.
Shokoples BG; Paradis P; Schiffrin EL
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):186-199. PubMed ID: 32998520
[TBL] [Abstract][Full Text] [Related]
19. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target.
Zhou H; Li N; Yuan Y; Jin YG; Guo H; Deng W; Tang QZ
Basic Res Cardiol; 2018 Aug; 113(5):37. PubMed ID: 30094473
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of sphingosine-1-phosphate (S1P).
Levkau B
Handb Exp Pharmacol; 2013; (216):147-70. PubMed ID: 23563656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
